223 related articles for article (PubMed ID: 15494294)
1. Transplant strategies for myelodysplastic syndrome.
McCarty J
Best Pract Res Clin Haematol; 2004 Dec; 17(4):559-72. PubMed ID: 15494294
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Transplant strategies for patients with myelodysplastic syndromes.
Deeg HJ
Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
[TBL] [Abstract][Full Text] [Related]
5. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
de Lima M; Giralt S
Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
[TBL] [Abstract][Full Text] [Related]
7. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
8. Hemopoietic cell transplantation for the myelodysplastic syndromes.
Scott BL; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation for myelodysplastic syndrome.
Barrett AJ; Savani BN
Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
[TBL] [Abstract][Full Text] [Related]
10. Transplantation strategies for the management of patients with myelodysplastic syndromes.
Meletis J; Terpos E
J BUON; 2009; 14(4):551-64. PubMed ID: 20148443
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
[TBL] [Abstract][Full Text] [Related]
13. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
[TBL] [Abstract][Full Text] [Related]
14. [Role of aggressive treatment strategies for myelodysplastic syndromes].
Aul C; Germing U; Minning H; Kobbe G; Gattermann N; Südhoff T; Meckenstock G; Söhngen D; Heyll A
Praxis (Bern 1994); 1999 Mar; 88(10):431-8. PubMed ID: 10199215
[TBL] [Abstract][Full Text] [Related]
15. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
16. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
17. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome.
de Witte T; Oosterveld M; Muus P
Blood Rev; 2007 Jan; 21(1):49-59. PubMed ID: 16822600
[TBL] [Abstract][Full Text] [Related]
18. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
19. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
20. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
Haematologica; 2006 Jun; 91(6):750-6. PubMed ID: 16769576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
